United States: PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent - Goodwin Procter LLP
Thursday, 29 February 2024
Late last month, a Patent Trial and Appeal Board ("PTAB") panel instituted two petitions that were filed separately by Celltrion and Biocon for inter partes review ("IPR") of Regeneron's U.S.
|
||||
You Might Like |
||||
